Genedata Expands Partnership with MorphoSys to Support New Antibody Libraries and Developability Assessment
Successful expansion of Genedata Biologics workflow platform to automate and streamline antibody discovery operations at MorphoSys
June 7, 2016
Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced that Genedata has broadened its relationship with MorphoSys. Under the expanded collaboration, Genedata has successfully implemented new Genedata Biologics™ capabilities to further streamline MorphoSys’ antibody discovery and optimization workflows and to broaden integration with MorphoSys’ latest automation platforms. MorphoSys, partnering with Genedata since 2009, uses the Genedata Biologics platform as the underlying workflow system for their entire partnered and proprietary discovery programs. The platform is used across the full MorphoSys technology portfolio, including the latest phage library technologies Ylanthia®, Slonomics® and the established HuCAL® Platinum and Gold libraries.
“The scale and throughput of our operations necessitated the use of an enterprise workflow platform to manage and streamline the growing number of our discovery programs,” said Dr. Markus Enzelberger, Senior Vice President and Head of Discovery, Alliances and Technologies at MorphoSys. “We made a decision early on to use Genedata Biologics as MorphoSys’ workflow backbone to accelerate our drug discovery efforts and have watched as Genedata Biologics has become the global industry standard for biopharma discovery organizations. We are pleased to see the steady and continuous evolution of the Genedata Biologics platform and how it addresses our consistently emerging new technology and workflow requirements.”
Genedata Biologics is used to support MorphoSys’ discovery operations, covering antibody screening, protein engineering, expression, purification, characterization, and analytics workflows. The platform enables MorphoSys to increase throughput in antibody generation and testing, rapidly analyzing and interpreting all candidate data as a basis for informed decision-making. In particular, it identifies drug candidates with superior developability and manufacturability profiles and guides the simultaneous optimization of their functional, expression, or biophysical properties.
“We appreciate the collaborative approach with Genedata, and their unique expertise in biopharma discovery and process optimization,” continued Dr. Enzelberger.
“We are very proud that MorphoSys, a leader in biopharma R&D innovation, has expanded their usage and application scope of Genedata Biologics. MorphoSys is one of our early partners, and it is a pleasure to see how our relationship has grown over the years,” said Dr. Othmar Pfannes, CEO of Genedata. “Genedata continues to make significant investments in the Genedata Biologics platform to ensure that our partners have access to the most advanced biopharma R&D workflow platform in the industry."
In the last few years, Genedata Biologics has been rapidly adopted by the majority of the world’s leading biopharmaceutical companies. Genedata’s collaborations range from single group installations to large, global, multi-site partnerships and include technology transfer, customizations, project management, training, and roll out and deployment support.
Genedata transforms data into intelligence with innovative software solutions and domain-specific consulting services that automate complex, large-scale experimental processes and enable organizations to maximize the ROI in their R&D, spanning early discovery all the way to the clinic. Founded in 1997, Genedata is headquartered in Switzerland with additional offices in Germany, Japan, Singapore, the UK, and the US.
LinkedIn | Twitter | YouTube
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.